A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
Phase:
PHASE1
Details
Lead Sponsor:
Aptamer Sciences, Inc.
Collaborators:
CHA University National Cancer Center, Korea Samsung Medical Center Severance Hospital